AstraZeneca has sent a legal notice to Serum Institute of India, which is manufacturing its COVID-19 vaccine, over supply delays, CEO Adar Poonawalla said. "We are examining all avenues to...resolve legal disputes over contractual obligations that Serum Institute isn't able to fulfil due to its prioritisation of Indian supplies," he added. Serum Institute has so far exported 60 million doses.